HUM

Business Context and Reporting Period

Company: Humana Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: Humana is a major health benefits company operating two primary segments: Government (Medicare, TRICARE, Medicaid) and Commercial (employer groups, individuals). The quarter marked the first full quarter of operations for the new Medicare Part D prescription drug program (PDP), which significantly expanded membership and revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 38.9% year-over-year, driven primarily by a 127.4% surge in Medicare premiums due to the launch of stand-alone PDP products and growth in Medicare Advantage members.
• Net Income Decline: Despite revenue growth, net income decreased 21.6% to $83.7 million. This was caused by higher SG&A expenses related to Medicare expansion and a higher effective tax rate (36.2% in 2006 vs. 8.5% in 2005, the latter benefiting from a one-time $22.8 million tax gain resolution).
• Cash Flow Surge: Operating cash flow increased dramatically to $1.008 billion, largely due to the timing of Medicare premium receipts (four monthly payments received in Q1 2006 vs. three in Q1 2005) and enrollment growth.
• Segment Performance:
  • Government Segment: Income before taxes dropped 69.4% to $21.6 million due to high initial costs and a 96.4% MER for new PDP products.
  • Commercial Segment: Income before taxes rose 137.3% to $109.6 million, aided by a lower MER (80.1%) and improved underwriting margins.
• Accounting Change: The company adopted SFAS 123R (Share-Based Payment) on January 1, 2006, requiring the expensing of stock options, which resulted in a restatement of prior period results.

Guidance, Outlook, and Risks

• Outlook: Management expects full-year 2006 Medicare premium revenues to more than double relative to 2005. Earnings are expected to be lower in the first half of 2006 and higher in the second half as PDP medical expense ratios improve and SG&A leverage increases.
• Full Year Guidance:
  • Effective tax rate expected to range between 35% and 37%.
  • Consolidated SG&A expense ratio expected to improve to 13%–14% for the full year.
  • Capital expenditures expected to range between $125 million and $135 million.
  • Capital contributions to subsidiaries expected to range between $500 million and $600 million.
• Risks and Contingencies:
  • Government Contracts: Significant exposure to Medicare and TRICARE contracts; changes in reimbursement rates or enrollment could materially impact results.
  • Legal Proceedings: A $40 million settlement regarding managed care industry class action litigation was approved by the court, with payments pending appeal resolution.
  • Medical Cost Inflation: Rising healthcare costs and prescription drug utilization remain key risks to profitability.

Investor Verification Checklist

• PDP Medical Expense Ratio Trend: Verify if the Medical Expense Ratio for stand-alone PDP plans improves in subsequent quarters as projected (expected to decline as members move through benefit stages).
• Medicare Enrollment Growth: Confirm continued growth in Medicare Advantage and PDP membership through the second quarter enrollment period.
• SG&A Leverage: Monitor if SG&A expense ratios compress in the second half of the year as marketing spend decreases and membership stabilizes.
• Legal Settlement Finality: Track the status of appeals regarding the $40 million managed care litigation settlement to determine the timing of cash outflows.
• Capital Requirements: Verify the actual amount of capital contributions required for state-regulated subsidiaries against the $500–$600 million estimate.